The C-Series air-operated double-diaphragm (AODD) pump from Almatec, part of PSG, a Dover company, is an alternative to similar plastic pumps and is suited for almost any pumping application that uses an oscillating pump.
The C-Series air-operated double-diaphragm (AODD) pump from Almatec, part of PSG, a Dover company, is an alternative to similar plastic pumps and is suited for almost any pumping application that uses an oscillating pump.
The design enables the housing parts to be jointly tightened via housing bolts; all bolts are tightened together against a diaphragm-sized ring on each side of the pump. Forces of the housing bolts distribute onto the housing parts evenly, providing a consistent flow of forces that increases bolt torque and improves pump safety, as stated by the company. The design also ensures the suction and discharge ports are available as separate housing parts so that different connection versions are available for easy matching to existing installations.
The pumps feature self-priming and dry run capabilities and do not have mechanical seals, drives, nor rotating parts that cause wear over time, the company reports. Available sizes include C 10 (3/8 in.), C 15 (1/2 in.), and C 25 (1 in.) and achieve flow rates from 1.3–7 m3/h at a maximum discharge pressure of 7 bar (100 psig). The wetted housing parts are made of either abrasion-resistant polyethylene or chemically, almost universally resistant polytetrafluoroethylene. The material of the non-wetted center block is polyethylene or polyethylene conductive.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.